Our results were consistent with previous studies on the expression of SALL4 in other types of cancers.38 Additionally, studies also indicated that radiotherapy alone could successfully control less T3‐4 tumors than T1‐2 tumors, meaning T3‐4 tumors might be more resistant to radiotherapy.40 Thus, a high expression of SALL4 might compose an adverse prognostic factor for the survival and radiosensitivity of NPC patients. The gene discussed is SALL4; the disease is cancer.